Figs Shares Rise 9.3% After Boost to Sales Guidance
By Paul Ziobro
Shares of Figs rose in late trading after the medical scrubs company boosted its sales growth outlook for the year.
The stock was up 9.3% to $6.14 in after-hours trading on Thursday, following a gain of 6.2% in the regular trading session. Through Thursday's close the stock was down 17% this year.
Figs now expects sales to rise 8.5% this year, compared to a prior forecast for sales to grow between 5.5% to 7.5%.
The raised view comes after the company reported a profit of $6.1 million, or 3 cents a share, for the quarter-ended Sept. 30, compared with $4 million, or 2 cents, in the year-ago period. Analysts polled by FactSet expected 2 cents a share.
Sales rose 10.7% to $142.4 million, on more orders from new and existing customers. Analysts' expected $131.4 million.
Chief Executive Trina Spear said the company's revenue and adjusted earnings before interest, tax, depreciation and amortization exceeded internal expectations.
Figs also said it added former Chewy Chief Financial Officer Mario Marte to its board, effective Nov. 3.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
November 02, 2023 17:35 ET (21:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software